Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
665.00    -7.00 (-1.04%)
Bid:
664.00
Ask:
666.00
Spread: 2.00 (0.301%)
Market Cap: £541.28m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

AGM Trading Update

16 Jul 2024 07:00

RNS Number : 4837W
Bloomsbury Publishing PLC
16 July 2024
 

BLOOMSBURY PUBLISHING PLC 

("Bloomsbury" or "the Company")

 

AGM Trading Update

Strong trading in-line with recently upgraded expectations

Bloomsbury Publishing Plc (LSE: BMY), the leading independent publisher, today announces its trading update for the four months ended 30 June 2024 ahead of the Company's Annual General Meeting ("AGM") at 12.00pm today.

Bloomsbury's trading has been in line with recently upgraded expectations, including the acquisition of Rowman and Littlefield's academic publishing business,* following a strong performance in the first four months of its financial year.

Consumer bestsellers in the period include:

· Sarah J. Maas' titles across all three of her bestselling series: Crescent City, Throne of Glass and A Court of Thorns and Roses;

· J.K. Rowling's Harry Potter series;

· Cixin Liu's The Three Body Problem, which is now also a Netflix series;

· Stuart Turton's The Last Murder at the End of the World, a No. 1 Sunday Times Bestseller;

· Hugh Fearnley-Whittingstall's How to Eat 30 Plants A Week, a No. 1 Sunday Times Bestseller;

· Tom Kerridge Cooks Britain, accompanying the TV series; and

· Johann Hari's Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs.

Exciting new releases for the summer include Sally Smith's A Case of Mice and Murder, Josephine Quinn's How the World Made the West, a Financial Times pick for Best History Book of 2024, and Mayowa and the Sea of Words by Chibundu Onuzo.

The Non-Consumer division included continued growth in Bloomsbury Digital Resources (BDR). On 29 May 2024, Bloomsbury announced the transformational acquisition of Rowman and Littlefield's academic publishing business, making Bloomsbury a leading US academic publisher with c.97,000 titles. The enlarged Academic business will focus on wider international sales, subject area expansion and continued innovation in digital scholarship and learning. This strategically important acquisition and our organic growth will accelerate BDR from 2023/2024's revenue of £27m to our increased BDR revenue target for 2027/28 of £41m, as Bloomsbury applies its proven ability to create premium digital content for the first time to Rowman & Littlefield's market leading titles, expanding BDR products.

The Board is confident in the medium and long-term strategy for Consumer and investing in Academic & Professional Publishing, with the benefits of digital content. We continue to execute our strategy of diversification across formats, territories and markets, reflecting our portfolio of portfolios strategy. Our authors, customers, consistent performance and the scale and resilience of our business continue to underpin the confidence we have in the future.

We will provide further details about the year ending 28 February 2025 with our Interim Results announcement.

*The Board considers current consensus market expectation for the year ending 28 February 2025 to be revenue of £319.3m and profit before taxation and highlighted items of £37.6m.

For further information, please contact:

Bloomsbury Publishing Plc

Tamsin Garrity, Head of Investor Relations

tamsin.garrity@bloomsbury.com

Hudson Sandler

+44 (0) 20 7796 4133

Dan de Belder / Hattie Dreyfus / Emily Brooker

bloomsbury@hudsonsandler.com

 

 Disclaimer

The information in this announcement has not been audited or otherwise independently verified and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of the Company or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this announcement, or its contents, or otherwise arising in connection with this announcement.

This announcement does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment or investment decisions relating thereto, nor does it constitute a recommendation regarding the shares of the Company.

Certain statements, statistics and projections in this announcement are or may be forward looking. By their nature, forward‑looking statements involve a number of risks, uncertainties or assumptions that may or may not occur and actual results or events may differ materially from those expressed or implied by the forward-looking statements. Accordingly, no assurance can be given that any particular expectation will be met and reliance should not be placed on any forward-looking statement. Accordingly, forward-looking statements contained in this announcement regarding past trends or activities should not be taken as representation that such trends or activities will continue in the future. You should not place undue reliance on forward-looking statements, which are based on the knowledge and information available only at the date of this announcement's preparation.

The Company does not undertake any obligation to update or keep current the information contained in this announcement, including any forward‑looking statements, or to correct any inaccuracies which may become apparent and any opinions expressed in it are subject to change without notice.

References in this announcement to other reports or materials, such as a website address, have been provided to direct the reader to other sources of information on Bloomsbury Publishing Plc which may be of interest. Neither the content of Bloomsbury's website nor any website accessible by hyperlinks from Bloomsbury's website nor any additional materials contained or accessible thereon, are incorporated in, or form part of, this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGPUPAMUPCGQA
Date   Source Headline
22nd May 20268:38 amRNSHolding(s) in Company
20th May 20267:00 amRNSAppointment of Non-Executive Director
20th May 20267:00 amRNSAudited Preliminary Results
12th May 20267:00 amRNSNotice of Preliminary Results
30th Apr 20262:47 pmRNSHolding(s) in Company
23rd Apr 202612:25 pmRNSHolding(s) in Company
15th Apr 202612:49 pmRNSAppointment of Executive Director - Replacement
15th Apr 20267:00 amRNSAppointment of Executive Director
1st Apr 20269:00 amRNSHolding(s) in Company
24th Mar 20267:22 amRNSHolding(s) in Company
19th Mar 20261:15 pmRNSHolding(s) in Company
5th Mar 20267:00 amRNSTrading Update
18th Feb 20265:51 pmRNSHolding(s) in Company
13th Feb 202610:21 amRNSBLOCK LISTING SIX MONTHLY RETURN
12th Feb 20264:39 pmRNSHolding(s) in Company
28th Jan 20267:00 amRNS-RBloomsbury to grow Academic sales in Asia
8th Dec 202510:05 amRNSDirector/PDMR Shareholding
3rd Dec 20257:00 amRNSGoogle and Bloomsbury Strategic Collaboration
19th Nov 202511:53 amRNSHolding(s) in Company
23rd Oct 20257:00 amRNSUnaudited Interim Results
8th Oct 20257:00 amRNS-RAuthor Katherine Rundell announces multi-film deal
2nd Oct 20255:22 pmRNSHolding(s) in Company
22nd Sep 20254:20 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSAppointment of Chief Financial & Operating Officer
29th Aug 20253:39 pmRNSDirector/PDMR Shareholding
28th Aug 20254:16 pmRNSDirector/PDMR Shareholding
28th Aug 20253:51 pmRNSDirector/PDMR Shareholding
15th Aug 20259:34 amRNSBLOCK LISTING SIX MONTHLY RETURN
13th Aug 202512:11 pmRNSDirector/PDMR Shareholdings - Correction
12th Aug 20254:29 pmRNSDirector/PDMR Shareholding
11th Aug 202511:08 amRNSDirector/PDMR Shareholding
5th Aug 202511:31 amRNSHolding(s) in Company
1st Aug 20251:14 pmRNSDirector/PDMR Shareholding
31st Jul 202511:10 amRNSDirector/PDMR Shareholding
30th Jul 20253:55 pmRNSHolding(s) in Company
29th Jul 20253:08 pmRNSHolding(s) in Company
28th Jul 20254:39 pmRNSHolding(s) in Company
25th Jul 20253:13 pmRNSHolding(s) in Company
24th Jul 20253:48 pmRNSHolding(s) in Company
17th Jul 20253:46 pmRNSHolding(s) in Company
16th Jul 20253:16 pmRNSResults of the 2025 Annual General Meeting
16th Jul 20257:00 amRNSAGM Trading Update
15th Jul 20254:14 pmRNSHolding(s) in Company
4th Jul 20253:54 pmRNSHolding(s) in Company
2nd Jul 20254:39 pmRNSHolding(s) in Company
13th Jun 20255:33 pmRNSAnnual Financial Report
22nd May 20257:00 amRNSAnnual Financial Report
15th May 20257:00 amRNSNotice of Preliminary Results
15th Apr 20257:00 amRNSAppointment of Joint Corporate Broker
20th Mar 20257:00 amRNSTrading Update and Board Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.